Uniquely targeting metabolic defects in neurodegenerative disorders
disease (AD) remains a largely untreated condition. Development
of effective treatments relies on identifying the underlying
factors that give rise to the clinical symptoms of the disease.
One such target is the well characterized decrease in glucose
metabolism that occurs in the brain of an Alzheimer’s patient,
commonly referred to as cerebral "hypometabolism."
Accera is developing novel therapies that target this metabolic defect and may lead to new products for this devastating disease.
The main fuel for the brain is the sugar glucose. The brain rarely uses fat as a fuel. Therefore, defects in the brain’s ability to use glucose have broad deleterious consequences. Low rates of glucose metabolism can result in disturbances in cholesterol homeostasis, cholinergic defects, and altered processing and clearing of cellular proteins - all of which are physiological hallmarks of AD.
Regional defects in glucose utilization have been well documented in AD and can be detected in at-risk populations, as early as 30 years of age, decades before clinical symptoms arise. The cause of the hypometabolism remains uncertain, but may be related to disturbances in lipid metabolism. Membrane proteins, such as glucose transporters, rely on specific lipid environments in which to function. If these environments are not ideal, glucose transporters and other membrane proteins may function poorly. Hence, altered lipid metabolism may also be at the heart of AD. This is consistent with the findings that variation in the lipid transport gene, Apolipoprotein E, is the major risk factor or the most common form of AD.
Accera has developed a novel strategy to alleviate cerebral hypometabolism. This product is designed to increase energy to the brain and provide raw materials for cholesterol and acetylcholine synthesis. Accera's revolutionary approach is unique among companies developing therapeutics for AD.
Accera’s approach is to provide alternative energy to the brain. Accera’s therapeutic approach produces an alternative to glucose known as ketone bodies. Ketone bodies consist of beta-hydroxybutyrate, acetoacetate and acetone. Hence ketone bodies are well suited as a supplemental energy source for cells with compromised glucose metabolism. Accera’s technology produces ketone bodies without the need for fasting or difficult dietary modification.
The video below gives an animated explanation of hypometabolism, the physiological hallmark of AD, and our therapeutic approach using ketone bodies. This approach has been validated in preclinical and clinical studies with our product, Axona®, available by prescription in the United States.
The brochure below gives a brief explanation of hypometabolism, the physiological hallmark of AD, and our therapeutic approach using ketones.
Science Brochure - PDF